Closing the Gap: Elinzanetant Demonstrates Efficacy For Vasomotor Symptoms in African American Women
This educational program features Genevieve Neal-Perry, MD, PhD, discussing the disproportionate burden of vasomotor symptoms among African American women and the need for equitable, evidence-based menopause care. Across multiple segments, Neal-Perry reviews the design and pooled efficacy data from the OASIS 1 and 2 trials, demonstrating that elinzanetant (Lynkuet) significantly reduces hot flash frequency and severity, improves sleep, and enhances quality of life across racial subgroups, with rapid onset of benefit and a favorable safety profile.